1. Home
  2. IIIN vs CABA Comparison

IIIN vs CABA Comparison

Compare IIIN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IIIN

Insteel Industries Inc.

N/A

Current Price

$30.58

Market Cap

484.9M

Sector

Industrials

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$3.55

Market Cap

495.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IIIN
CABA
Founded
1953
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
484.9M
495.7M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
IIIN
CABA
Price
$30.58
$3.55
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
128.7K
4.7M
Earning Date
04-16-2026
05-14-2026
Dividend Yield
4.37%
N/A
EPS Growth
112.12
10.26
EPS
1.12
N/A
Revenue
$647,706,000.00
N/A
Revenue This Year
$14.20
N/A
Revenue Next Year
$6.82
N/A
P/E Ratio
$27.09
N/A
Revenue Growth
22.39
N/A
52 Week Low
$24.35
$1.56
52 Week High
$39.91
$4.23

Technical Indicators

Market Signals
Indicator
IIIN
CABA
Relative Strength Index (RSI) 48.19 69.57
Support Level $30.49 $2.58
Resistance Level $31.04 $3.67
Average True Range (ATR) 0.72 0.23
MACD -0.14 0.05
Stochastic Oscillator 37.01 94.64

Price Performance

Historical Comparison
IIIN
CABA

About IIIN Insteel Industries Inc.

Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: